193 related articles for article (PubMed ID: 35359589)
1. Mechanism of Peptide Agonist Binding in CXCR4 Chemokine Receptor.
Pawnikar S; Miao Y
Front Mol Biosci; 2022; 9():821055. PubMed ID: 35359589
[TBL] [Abstract][Full Text] [Related]
2. Pathway and mechanism of drug binding to chemokine receptors revealed by accelerated molecular simulations.
Pawnikar S; Miao Y
Future Med Chem; 2020 Jul; 12(13):1213-1225. PubMed ID: 32515227
[No Abstract] [Full Text] [Related]
3. Mechanistic Insights into Peptide Binding and Deactivation of an Adhesion G Protein-Coupled Receptor.
Adediwura VA; Miao Y
Molecules; 2023 Dec; 29(1):. PubMed ID: 38202747
[TBL] [Abstract][Full Text] [Related]
4. Identification of allosteric peptide agonists of CXCR4.
Sachpatzidis A; Benton BK; Manfredi JP; Wang H; Hamilton A; Dohlman HG; Lolis E
J Biol Chem; 2003 Jan; 278(2):896-907. PubMed ID: 12417595
[TBL] [Abstract][Full Text] [Related]
5. Fluorescent CXCL12AF647 as a novel probe for nonradioactive CXCL12/CXCR4 cellular interaction studies.
Hatse S; Princen K; Liekens S; Vermeire K; De Clercq E; Schols D
Cytometry A; 2004 Oct; 61(2):178-88. PubMed ID: 15382150
[TBL] [Abstract][Full Text] [Related]
6. Allosteric peptide regulators of chemokine receptors CXCR4 and CXCR7.
Ehrlich A; Ray P; Luker KE; Lolis EJ; Luker GD
Biochem Pharmacol; 2013 Nov; 86(9):1263-71. PubMed ID: 23973527
[TBL] [Abstract][Full Text] [Related]
7. Peptide Gaussian accelerated molecular dynamics (Pep-GaMD): Enhanced sampling and free energy and kinetics calculations of peptide binding.
Wang J; Miao Y
J Chem Phys; 2020 Oct; 153(15):154109. PubMed ID: 33092378
[TBL] [Abstract][Full Text] [Related]
8. Differential activity and selectivity of N-terminal modified CXCL12 chemokines at the CXCR4 and ACKR3 receptors.
Jaracz-Ros A; Bernadat G; Cutolo P; Gallego C; Gustavsson M; Cecon E; Baleux F; Kufareva I; Handel TM; Bachelerie F; Levoye A
J Leukoc Biol; 2020 Jun; 107(6):1123-1135. PubMed ID: 32374043
[TBL] [Abstract][Full Text] [Related]
9. A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II.
Zhou N; Luo Z; Luo J; Hall JW; Huang Z
Biochemistry; 2000 Apr; 39(13):3782-7. PubMed ID: 10736178
[TBL] [Abstract][Full Text] [Related]
10. The CXCL12/CXCR4 axis as a therapeutic target in cancer and HIV-1 infection.
Patrussi L; Baldari CT
Curr Med Chem; 2011; 18(4):497-512. PubMed ID: 21143114
[TBL] [Abstract][Full Text] [Related]
11. Activation of Polycystin-1 Signaling by Binding of Stalk-derived Peptide Agonists.
Pawnikar S; Magenheimer BS; Munoz EN; Haldane A; Maser RL; Miao Y
bioRxiv; 2024 Jan; ():. PubMed ID: 38260358
[TBL] [Abstract][Full Text] [Related]
12. The CXCR4 agonist ligand stromal derived factor-1 maintains high affinity for receptors in both Galpha(i)-coupled and uncoupled states.
Di Salvo J; Koch GE; Johnson KE; Blake AD; Daugherty BL; DeMartino JA; Sirotina-Meisher A; Liu Y; Springer MS; Cascieri MA; Sullivan KA
Eur J Pharmacol; 2000 Dec; 409(2):143-54. PubMed ID: 11104827
[TBL] [Abstract][Full Text] [Related]
13. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140.
Tamamura H; Xu Y; Hattori T; Zhang X; Arakaki R; Kanbara K; Omagari A; Otaka A; Ibuka T; Yamamoto N; Nakashima H; Fujii N
Biochem Biophys Res Commun; 1998 Dec; 253(3):877-82. PubMed ID: 9918823
[TBL] [Abstract][Full Text] [Related]
14. The chemical diversity and structure-based evolution of non-peptide CXCR4 antagonists with diverse therapeutic potential.
Peng D; Cao B; Zhou YJ; Long YQ
Eur J Med Chem; 2018 Apr; 149():148-169. PubMed ID: 29500940
[TBL] [Abstract][Full Text] [Related]
15. Neutralising properties of peptides derived from CXCR4 extracellular loops towards CXCL12 binding and HIV-1 infection.
Chevigné A; Fievez V; Szpakowska M; Fischer A; Counson M; Plesséria JM; Schmit JC; Deroo S
Biochim Biophys Acta; 2014 May; 1843(5):1031-41. PubMed ID: 24480462
[TBL] [Abstract][Full Text] [Related]
16. Ligand selectivity of a synthetic CXCR4 mimetic peptide.
Groß A; Brox R; Damm D; Tschammer N; Schmidt B; Eichler J
Bioorg Med Chem; 2015 Jul; 23(14):4050-5. PubMed ID: 25801155
[TBL] [Abstract][Full Text] [Related]
17. Partial agonist activity of α1-adrenergic receptor antagonists for chemokine (C-X-C motif) receptor 4 and atypical chemokine receptor 3.
Gao X; Abdelkarim H; Albee LJ; Volkman BF; Gaponenko V; Majetschak M
PLoS One; 2018; 13(9):e0204041. PubMed ID: 30248140
[TBL] [Abstract][Full Text] [Related]
18. Gaussian accelerated molecular dynamics for elucidation of drug pathways.
Bhattarai A; Miao Y
Expert Opin Drug Discov; 2018 Nov; 13(11):1055-1065. PubMed ID: 30371112
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for chemokine recognition by a G protein-coupled receptor and implications for receptor activation.
Ziarek JJ; Kleist AB; London N; Raveh B; Montpas N; Bonneterre J; St-Onge G; DiCosmo-Ponticello CJ; Koplinski CA; Roy I; Stephens B; Thelen S; Veldkamp CT; Coffman FD; Cohen MC; Dwinell MB; Thelen M; Peterson FC; Heveker N; Volkman BF
Sci Signal; 2017 Mar; 10(471):. PubMed ID: 28325822
[TBL] [Abstract][Full Text] [Related]
20. Structural basis of the interactions between CXCR4 and CXCL12/SDF-1 revealed by theoretical approaches.
Xu L; Li Y; Sun H; Li D; Hou T
Mol Biosyst; 2013 Aug; 9(8):2107-17. PubMed ID: 23702796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
